Analyst Price Targets — LLY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 10, 2026 12:56 pm | — | Morgan Stanley | $1,327.00 | $939.31 | TheFly | Eli Lilly price target raised to $1,327 from $1,313 at Morgan Stanley |
| March 13, 2026 12:09 pm | Akash Tewari | Jefferies | $1,300.00 | $1,000.78 | StreetInsider | Jefferies Reiterates Buy Rating on Eli Lilly (LLY): 'early oral Wegovy launch is directionally encouraging' |
| March 6, 2026 3:39 pm | James Shin | Deutsche Bank | $1,285.00 | $990.31 | StreetInsider | Deutsche Bank Reiterates Buy Rating on Eli Lilly (LLY) following aggregate scripts |
| March 5, 2026 1:04 pm | Terence Flynn | Morgan Stanley | $1,313.00 | $972.50 | StreetInsider | Morgan Stanley Reiterates Overweight Rating on Eli Lilly (LLY) following Employer Connect launch |
| February 24, 2026 9:06 pm | Trung Huynh | RBC Capital | $1,250.00 | $1,042.15 | StreetInsider | RBC Capital Starts Eli Lilly (LLY) at Outperform |
| February 19, 2026 9:12 pm | — | Barclays | $1,350.00 | $1,023.22 | TheFly | Eli Lilly initiated with an Overweight at Barclays |
| February 10, 2026 8:24 pm | Ilya Zubkov | Loop Capital Markets | $1,200.00 | $1,025.00 | StreetInsider | Freedom Capital Markets Upgrades Eli Lilly (LLY) to Buy |
| February 5, 2026 3:43 pm | — | Scotiabank | $1,300.00 | $1,037.13 | TheFly | Eli Lilly price target raised to $1,300 from $1,165 at Scotiabank |
| February 5, 2026 3:05 pm | — | Truist Financial | $1,281.00 | $1,027.51 | TheFly | Eli Lilly price target raised to $1,281 from $1,182 at Truist |
| February 5, 2026 12:50 pm | — | Goldman Sachs | $1,260.00 | $1,107.12 | TheFly | Eli Lilly price target raised to $1,260 from $1,145 at Goldman Sachs |
Latest News for LLY
Eli Lilly and Co. (LLY) may be starting to regain some footing after recent regulatory scrutiny weighed on sentiment around its newly approved obesity pill, Found
Eli Lilly (LLY) is looking to get more out of its obesity pill Foundayo, moving to expand its use into diabetes after a strong late stage trial.The data gives i
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
LLY stock slips after FDA seeks added safety data on its new oral obesity pill Foundayo, raising questions despite blockbuster sales hopes.
XLRP is a severe, progressive genetic eye disease causing early-onset night blindness and peripheral vision loss, leading to legal blindness by age 40–45.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.